To determine whether combination of olaparib and everolimus is synergistic in BRCA2 mutated cells, we performed drug combination cell viability assays in two triple-negative breast cancer cell lines, HCC1395 (BRCA2 mutated) [21, 22] and BT20 (PI3KCA mutated) [22]. The gene discussed is BRCA2; the disease is triple-negative breast carcinoma.